BioSpace2d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
FDA approves a new pain med that could eliminate addiction. When can GA patients get it?
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
MarketWatch2d
U.K. 30 Year Gilt
Japan 30 Year Government Bond 0.0000 2.2872% ...
Medscape2d
Efficacy, Safety and Tolerability of Escitalopram in Doses up to 50 mg in Major Depressive Disorder (MDD)
Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 ...
FDA Approves the First Non-Opioid Pain Medicine in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...
Healthline6d
Lisdexamfetamine, Oral Capsule
Severe kidney disease: The maximum dosage of lisdexamfetamine is 50 mg per day. End stage kidney disease requiring dialysis: The maximum dosage of lisdexamfetamine is 30 mg per day. This drug has ...
Bloomberg L.P.22h
Egyptian Exchange EGX 30 Price Index
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...